iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor
January 04, 2018 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor Further evaluation of IDO1 inhibitor with clinically manageable safety profile to commence following review of Phase 1...
iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor
January 04, 2018 02:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor Further evaluation of IDO1 inhibitor with clinically manageable safety profile to commence following review of Phase 1...
iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting
November 06, 2017 07:01 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting Presentations to highlight new preclinical results for A2A antagonist and TIGIT antibody programs Gosselies,...
iTeos Therapeutics SA: iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
August 08, 2017 08:01 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference Gosselies, Belgium - August 8, 2017 - iTeos Therapeutics SA, a biotechnology company developing novel cancer...
iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region
July 28, 2017 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region Funding will support the clinical development of the Company's lead innovative immuno-oncology drug ...
iTeos Therapeutics SA: Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development
June 29, 2017 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Appoints Mohamed Ragab, M.D. as Vice President, Corporate DevelopmentJoins from Bristol Myers Squibb to accelerate global partnering Gosselies, Belgium - June 29, 2017 - iTeos...
iTeos Therapeutics SA: iTeos Therapeutics to Present Data for Novel A2A Receptor Antagonist at American Association for Cancer Research Annual Meeting
April 03, 2017 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Data for Novel A2A Receptor Antagonist at American Association for Cancer Research Annual Meeting Gosselies, Belgium - April 3, 2017 -- iTeos Therapeutics SA, a...
iTeos Therapeutics to Present at the 2017 BIO CEO & Investor Conference
February 10, 2017 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at the 2017 BIO CEO & Investor Conference Gosselies, Belgium - February 10, 2017 - iTeos Therapeutics SA, a Belgian privately-held biotechnology company applying...
Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal's CriPec® nanotech platform
December 07, 2016 08:49 ET
|
iTeos Therapeutics SA
Initial goal to determine treatment efficacy of iTeos' immuno-oncology drug candidatesOption for iTeos to license Cristal's proprietary nanotechnology platform for development of up to three...